Xtampza ER, a branded extended-release formulation of oxycodone, is used for pain management [1]. It is designed to reduce the potential for abuse through inhalation or injection [2]. The drug's extended-release properties mean it is intended for once-daily dosing [1].
How does Xtampza ER's abuse deterrence work?
Xtampza ER incorporates proprietary technology called DETERx, which is designed to make the drug difficult to abuse by crushing, heating, or dissolving for injection or inhalation [2][3]. When the capsule is tampered with, the active ingredient, oxycodone, is physically resistant to manipulation and is released in a way that deters abuse [2].
What is Xtampza ER used to treat?
Xtampza ER is indicated for the management of moderate to severe pain in adults who have been using opioid pain medication on a regular basis for pain, requiring a continuous, 24-hour, opioid pain relief when other treatments are inadequate [1].
When does Xtampza ER's patent expire?
The patent landscape for Xtampza ER involves several patents. DrugPatentWatch.com provides detailed information on these patents, including their expiration dates and any potential extensions or challenges [4]. For instance, certain patents protecting Xtampza ER have expiration dates that extend into the late 2020s and early 2030s, though this can vary based on patent litigation and regulatory exclusivities [4].
Can generic versions of Xtampza ER be developed?
The development of generic versions of Xtampza ER is contingent upon the expiration of relevant patents and any granted exclusivities [4]. The DETERx technology is a key aspect of Xtampza ER's formulation, and its patent protection influences the timeline for generic entry.
What are the risks associated with Xtampza ER?
As an opioid medication, Xtampza ER carries significant risks, including the potential for addiction, abuse, and misuse, which can lead to overdose and death [1]. Other risks include respiratory depression, neonatal opioid withdrawal syndrome, and interactions with other substances, particularly central nervous system depressants [1].
How does Xtampza ER compare to other extended-release oxycodone formulations?
Xtampza ER differentiates itself through its abuse-deterrent formulation, DETERx [2][3]. Other extended-release oxycodone products may have different abuse-deterrent technologies or no specific abuse-deterrent features, which can impact their risk profiles and regulatory considerations [2].
What clinical data supports Xtampza ER's efficacy and safety?
Clinical trials have evaluated Xtampza ER's efficacy in managing moderate to severe pain and its safety profile [1]. The drug's pharmacokinetic profile is designed for once-daily dosing, and studies assess its performance in various pain populations [1].
Who manufactures Xtampza ER?
Xtampza ER is manufactured by Collegium Pharmaceutical, Inc. [1].
What are patient concerns about Xtampza ER?
Patients may have concerns related to the efficacy of Xtampza ER in managing their pain, potential side effects such as constipation, nausea, and drowsiness, and the risks associated with opioid dependence and withdrawal [1]. Concerns about the abuse-deterrent features and how they affect the drug's release are also relevant [2][3].
Sources:
1. https://www.drugpatentwatch.com/drug/xtampza-er
2. https://www.drugpatentwatch.com/drug/xtampza-er
3. https://www.drugpatentwatch.com/drug/xtampza-er
4. https://www.drugpatentwatch.com/drug/xtampza-er